Evotec licenses CRISPR gene editing tech
Evotec AG has entered into a non-exclusive license agreement with the MIT’s Broad Institute and Harvard for the use of CRISPR-Cas9 gene editing technology.
Evotec AG has entered into a non-exclusive license agreement with the MIT’s Broad Institute and Harvard for the use of CRISPR-Cas9 gene editing technology.
Pluristem has said it will begin a US trial of a cell therapy for people lacking bone marrow this year after hiring a CRO.